Clinical Trial Update: Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating recombinant porcine factor VIII for patients with Hemophilia A and inhibitors to factor VIII has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Recombinant Porcine Factor VIII (porcine factor VIII (recombinant))

Snippet

Sponsor: Octagen Corporation | Conditions: Hemophilia A | Phase 2 | Status: COMPLETED